Zai Lab and Pfizer collaborate to address drug-resistant infections in China
Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising threat of drug-resistant infections caused by carbapenem-resistant ... Read More
Zai Lab treats first patient in China in PANOVA-3 trial of TTFields
Zai Lab Limited said that it has treated the first patient in Greater China in the PANOVA-3 phase 3 clinical trial of tumor treating fields ... Read More
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients ... Read More